跳至主要内容
临床试验/EUCTR2007-005403-17-NL
EUCTR2007-005403-17-NL进行中(未招募)不适用

A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma - Blue light uretero-renoscopy detecting upper tract urothelial cell carcinoma

GE Healthcare0 个研究点目标入组 15 人开始时间: 2007年12月12日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
GE Healthcare
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -. Patients with known UCC of the UUT
  • -. Patients with suspicion for UCC of the UUT based on one of the following:
  • -unilateral or bilateral ureter sampling (suspect or malignant cells on cytology)
  • -suspect or malignant cells on urine cytology, with negative bladder biopsies
  • -macroscopic tumor on previous uretero-renoscopy
  • -tumor seen on imaging techniques (ultrasound, IVP, CT, MRI)
  • -. Patients with ZUBROD-ECOG-WHO performance status of 0-2 (see appendix 1)
  • -. Patients must be over 18 years of age
  • -. Patients must be fully informed of the investigational nature of the study and signed written informed consent must be obtained prior to any study specific investigations
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -. Patients with existing or recurrent severe urinary tract infection
  • -. Gross haematuria (defined as heavy bleed resulting in marked amounts of blood in the urine, which may interfere with fluorescence uretero-renoscopy. Where the bleed is light, the patient should not be excluded if in the investigator’s opinion rinsing during uretro-renoscopy will alleviate the possible interference with fluorescence cystoscopy)
  • -. Patients with porphyria
  • -. Known allergy to hexyl aminolevulinate hydrochloride or a similar compound
  • -. Pregnant or breast-feeding (patients must use adequate birth control methods while on the study and for 4 weeks following the end of treatment)
  • -. Patients who have received BCG or chemotherapy in the UUT within 3 months prior to uretero-renoscopy
  • -. Conditions associated with a risk of poor protocol compliance

研究者

发起方
GE Healthcare

相似试验